Who is sponsoring NCT01645761?

NCT01645761 is sponsored by Chuncheon Sacred Heart Hospital.

What drugs are being tested in NCT01645761?

Interventions in NCT01645761: Endonase.

What condition does NCT01645761 study?

NCT01645761 studies Gastric Ulcer Associated With Helicobacter Pylori.

Is NCT01645761 still recruiting?

NCT01645761 is currently completed. Last updated 20 January 2014.

Last reviewed 2014-01-20 · How we verify

NCT01645761

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Additive Effect of Endonase on Eradication Rate of the 7-day Standard Proton Pump Inhibitor-based Triple Therapy for Helicobacter Pylori

Completed NA Last updated 20 January 2014

What this trial tests

NA trial testing Endonase in Gastric Ulcer Associated With Helicobacter Pylori in 112 participants. Completed in 1 August 2013.

Timeline

1 June 2012

Primary endpoint
1 August 2013

1 August 2013

Quick facts

Lead sponsor	Chuncheon Sacred Heart Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	112
Start date	1 June 2012
Primary completion	1 August 2013
Estimated completion	1 August 2013
Sites	1 location across South Korea

Drugs / interventions tested

Endonase — full drug profile →

Conditions studied

Gastric Ulcer Associated With Helicobacter Pylori — all drugs for Gastric Ulcer Associated With Helicobacter Pylori →

Sponsor

Chuncheon Sacred Heart Hospital

Who can join

18 and older, any sex, with Gastric Ulcer Associated With Helicobacter Pylori. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Eradication rate
Time frame: 4 weeks
Intention-to-treat analysis and per-protocol analysis to compare the eradication rate of the 7-day standard PPI-based triple therapy plus endonase with that of the 7-day standard PPI-based triple therapy

Sponsor's own description

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Additive Effect of Pronase on the Eradication Rate of First-Line Therapy for Helicobacter pylori Infection.
Bang CS, Kim YS, Park SH, Kim JB, et al · · 2015 · cited 13× · PMID 25167799 · DOI 10.5009/gnl13399

Verify or expand the search:

Other Chuncheon Sacred Heart Hospital trials

Trials by the same sponsor.

NCT07039955 — Effect of Daily Chlorhexidine Bathing and Antibiotic/PPI Stewardship on Prevention of CPE Transmission and Infection · NA · enrolling by invitation
NCT07001228 — Scapular Dyskinesis With Impingement Syndrome · NA · not yet recruiting
NCT06878391 — ISB With SSNB & ANB · NA · recruiting
NCT06055491 — Vitamin D3 Combined With Strengthening Exercise for Lateral Epicondylitis of Elbow · NA · unknown
NCT06055478 — Effect of Suprascapular Nerve Block and Axillary Nerve Block After Arthroscopic Rotator Cuff Repair · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01645761 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chuncheon Sacred Heart Hospital
Last refreshed: 20 January 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01645761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing